Agios Pharmaceuticals, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsAgios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare hematologic diseases, with mitapivat approved for thalassemia and PK deficiency and a pipeline of earlier-stage candidates.
What they do
Agios develops and commercializes therapies for rare diseases, primarily in hematology. Its lead product, mitapivat (PYRUKYND/AQVESME), is a pyruvate kinase activator approved for thalassemia and pyruvate kinase deficiency in multiple geographies. The company also develops tebapivat for myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, AG-236 for polycythemia vera, and cevidoplenib for immune thrombocytopenia.
Revenue drivers
- Mitapivat – U.S. (AQVESME for thalassemia, PYRUKYND for PK deficiency) — Drove $40.9 million in Q2 2026 U.S. net revenue, driven by the AQVESME launch in thalassemia (started late January 2026) and existing PK deficiency sales.
- Mitapivat – ex-U.S. (PYRUKYND) — Contributed $3.8 million in Q2 2026, reflecting EU approval for thalassemia (May 2026) and demand in Gulf Cooperation Council countries via managed access and partnership agreements.
Recent performance
Q2 2026 net product revenue was $44.7 million, up from $12.5 million in Q2 2025, with strong U.S. launch of AQVESME in thalassemia (442 cumulative prescriptions by June 30, 2026). Cash, equivalents, and marketable securities were $964.8 million at June 30, 2026. Revenue growth reflects early commercial traction in the U.S. and EU.
Strategy
Agios is scaling its commercial launch of AQVESME in thalassemia while expanding mitapivat into sickle cell disease via a priority-review sNDA and a confirmatory Phase 3 trial (REIGNITE). Management is diversifying the pipeline through licensing (e.g., cevidoplenib for ITP) and internal advancement (AG-236 into Phase 2/3 for polycythemia vera). They aim to maintain a disciplined capital allocation to support commercial execution and pipeline progress.
Risks
- Commercial launch execution — AQVESME is newly launched; revenues depend on physician and patient adoption, reimbursement, and competition in thalassemia.
- Regulatory uncertainty for sickle cell disease — The sNDA for mitapivat in SCD is under accelerated approval with a PDUFA date of November 1, 2026; the confirmatory trial REIGNITE is ongoing and success is not guaranteed.
- Dependence on mitapivat sales — Mitapivat is the only marketed product; the company is still unprofitable and incurs heavy R&D and SG&A costs, as shown by net losses in recent years.
- Milestone and royalty obligations — Agios owes potential milestone payments to Alnylam (up to $130M in development/regulatory milestones plus sales milestones and royalties) and to Oscotec for cevidoplenib.
Outlook
Management expects continued commercial momentum for AQVESME and PYRUKYND and anticipates a potential approval for mitapivat in sickle cell disease by November 1, 2026. They plan to advance cevidoplenib into Phase 3 in the first half of 2028 and progress AG-236 through Phase 2/3. With $964.8 million in cash, they state they are well capitalized to support these programs.